Login to Your Account

AstraZeneca, BTG Drug CytoFab Misses in Sepsis

By Cormac Sheridan
Staff Writer

Wednesday, August 15, 2012
The drug development graveyard that is sepsis claimed another victim last week, as AZD9773 (CytoFab), which AstraZeneca plc was developing with BTG plc, failed to separate from placebo in a Phase IIb trial in 300 patients with severe sepsis or septic shock.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription